Abivax (NASDAQ:ABVX – Get Free Report) and Forte Biosciences (NASDAQ:FBRX – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.
Insider and Institutional Ownership
47.9% of Abivax shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Abivax has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 2.87, indicating that its stock price is 187% more volatile than the S&P 500.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Abivax | N/A | N/A | -$380.27 million | ($5.21) | -17.81 |
| Forte Biosciences | N/A | N/A | -$69.38 million | ($4.64) | -3.99 |
Abivax is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Abivax and Forte Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Abivax | N/A | -99.02% | -70.26% |
| Forte Biosciences | N/A | -106.17% | -85.50% |
Analyst Ratings
This is a summary of current ratings and target prices for Abivax and Forte Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Abivax | 1 | 2 | 12 | 0 | 2.73 |
| Forte Biosciences | 1 | 0 | 3 | 0 | 2.50 |
Abivax currently has a consensus price target of $130.08, indicating a potential upside of 40.19%. Forte Biosciences has a consensus price target of $67.00, indicating a potential upside of 262.06%. Given Forte Biosciences’ higher possible upside, analysts plainly believe Forte Biosciences is more favorable than Abivax.
Summary
Forte Biosciences beats Abivax on 7 of the 11 factors compared between the two stocks.
About Abivax
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
About Forte Biosciences
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.
